In This Article:
HeartBeam has announced a partnership with electrocardiogram (ECG)-based diagnostics software company AccurKardia, aimed at improving cardiac monitoring solutions’ accessibility.
The alliance will focus on integrating AccurKardia's ECG analysis software, AccurECG, with HeartBeam's devices.
HeartBeam's cable-free, credit card-sized ECG device is designed to capture the electrical signals of the heart in three non-coplanar directions.
It synthesises them into a 12-lead ECG with the help of a personalised transformation matrix.
HeartBeam noted that it is preparing to begin commercialisation following the US Food and Drug Administration’s (FDA) clearance for the ECG synthesis software.
The addition of AccurKardia's device-agnostic automated ECG interpretation platform to HeartBeam's device is expected to improve the forthcoming commercial offering for arrhythmia evaluation.
It will allow both the physicians and their patients to receive an automated rhythm evaluation, potentially leading to rapid diagnosis and accessibility to necessary clinical care.
HeartBeam CEO Robert Eno said: “This collaboration is a major step forward in delivering a more accessible and scalable solution for remote cardiac monitoring.
“AccurKardia shares our mission of improving cardiac outcomes through technological innovation, and together we can accelerate the delivery of unprecedented cardiac insights to individuals and physicians outside of a medical facility.”
The partnership is anticipated to accelerate the product development of HeartBeam, minimising the expenses and time to market.
AccurKardia CEO and co-founder Juan Jimenez said: “By uniting our strengths, we’re creating a best‑in‑class platform that transforms how cardiac arrhythmia conditions are monitored and detected.
“Putting clinical-grade ECG insights directly into a patient’s pocket aims to meaningfully address the increasing lack of access to cardiology specialists in the US.”
Cleared by the FDA, AccurECG is a Class II software as a medical device designed for real-time ECG interpretation.
In March 2024, HeartBeam obtained two new patents from the US Patent and Trademark Office for its core vector electrocardiography (VECG) technology.
"HeartBeam partners with AccurKardia to enhance cardiac care" was originally created and published by Medical Device Network, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.